Press release

DSM delivers higher profits; full year outlook unchanged

Heerlen, NL, 06 Aug 2013 07:15 CEST

  • DSM records 19% higher Q2 EBITDA versus Q2 2012 (€345 million versus €290 million)
  • Nutrition EBITDA up 28% versus Q2 2012 driven by acquisitions and organic growth
  • Materials Sciences continues to deliver a solid performance
  • Q2 cash flow from operating activities €231 million, higher than Q2 2012 and Q1 2013
  • Core earnings per share Q2 2013 up 28% compared to Q2 2012
  • Interim dividend of €0.50, in line with DSM’s dividend policy
  • Outlook 2013 unchanged, moving towards EBITDA of €1.4 billion

Royal DSM, the Life Sciences and Materials Sciences company, today reported a second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013. The improvement compared to Q2 2012 was realized despite a negative caprolactam effect of €20 million and a challenging macro-economic environment, which mainly affected Materials Sciences. 

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “We are pleased to report that the momentum in our Nutrition business that we saw at the end of Q1 continued into Q2. Nutrition, with its higher profits and healthy margins, is demonstrating the quality of its broad offering across the value chain. Materials Sciences’ profit remained at the same level as last year despite a negative caprolactam impact of €20 million and a challenging market environment.”

For the rest of this year, we will continue to fully focus on operational performance and on the integration of our acquisitions, ensuring the capture of synergies. In addition, the early successes of our profit improvement initiatives leave us confident that this group-wide program is well on track. We expect strong EBITDA growth in 2013, moving towards €1.4 billion.”

Key figures

Q2 2013 Q2 2012 +/- in € million volume price/mix exch. rates other
2,468 2,268 9% Net sales 6% -4% -1% 8%
1,108 899 23% Nutrition 6% -3% -2% 22%
187 182 3% Pharma 3% 1% -1%  
714 713 0% Performance Materials 6% -3% -2% -1%
375 389 -4% Polymer Intermediates 5% -8% -1%  
37 18   Innovation Center        
47 67   Corporate Activities        
Q2 2013 Q2 2012 +/- in € million H1 2013 H1 2012 +/-
345 290 19% EBITDA 656 596 10%
249 195 28% Nutrition 464 387 20%
14 17 -18% Pharma 22 22 0%
82 77 6% Performance Materials 162 156 4%
26 30 -13% Polymer Intermediates 55 99 -44%
-3 -10   Innovation Center -7 -25  
-23 -19   Corporate Activities -40 -43  
156 118 32% Core net profit 285 267 7%
141 114 24% Net profit, before exceptional items 262 259 1%
112 41 173% Net profit, after exceptional items 231 186 24%
0.91 0.71 28% Core EPS (€/share) 1.67 1.62 3%
0.79 0.67 18% Net EPS before exceptional items (€/share) 1.49 1.54 -3%
0.62 0.23 170% Net EPS after exceptional items (€/share) 1.31 1.10 19%
231 197   Cash flow from operations 153 294  
168 162   Capital expenditures (cash) 332 288  
      Net debt 2,266 1,668*  

* year-end 2012

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more